Effectiveness of bacteriophages in the sputum of cystic fibrosis patients

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages O983-O990

  Saussereau, E ^a,b   Vachier, I ^c   Chiron, R ^c   Godbert, B ^d   Sermet, I ^e   Dufour, N ^a,e,f   Pirnay, J P ^g   De Vos, D ^g   Carrie F ^h   Molinari, N ^c   Debarbieux, L ^a  

^a INSTITUT PASTEUR   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d CHU NANCY BRABOIS   (France)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^h Centre Hospitalier Beziers   (France)

Author keywords

Pseudomonas aeruginosa; Chronic infection; Phage therapy; Pulmonary infection

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; MEROPENEM; NEOMYCIN; PIPERACILLIN PLUS TAZOBACTAM; PRISTINAMYCIN; RIFAMPICIN; TEICOPLANIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIOPHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM; ADOLESCENT; BACTERIAL LOAD; BIOLOGICAL THERAPY; CLINICAL TRIAL; COMPLICATION; GROWTH, DEVELOPMENT AND AGING; MICROBIAL VIABILITY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PSEUDOMONAS INFECTION; PSEUDOMONAS PHAGE; TIME; VIROLOGY; YOUNG ADULT;

ANIMALIA; BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; BACTERIAL LOAD; BIOLOGICAL THERAPY; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MICROBIAL VIABILITY; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; SPUTUM; TIME FACTORS; YOUNG ADULT;

EID: 84920496550     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12712     Document Type: Article

References (27)

1. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
2. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-161.
3. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011; 9: 32.
4. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7: 523-530.
5. Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the netherlands. Eur J Clin Microbiol Infect Dis 2013; 32: 283-288.
6. Reyes A, Haynes M, Hanson N et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 2010; 466: 334-338.
7. Rodriguez-Valera F, Martin-Cuadrado AB, Rodriguez-Brito B et al. Explaining microbial population genomics through phage predation. Nat Rev Microbiol 2009; 7: 828-836.
8. Gomez P, Buckling A. Bacteria-phage antagonistic coevolution in soil. Science 2011; 332: 106-109.
9. Matos RC, Lapaque N, Rigottier-Gois L et al. Enterococcus faecalis prophage dynamics and contributions to pathogenic traits. PLoS Genet 2013; 9: e1003539.
10. Barr JJ, Auro R, Furlan M et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci USA 2013; 110: 10771-10776.
11. d'Herelle F. Sur un microbe invisible antagoniste des bacilles dysentériques. Les Comptes rendus de l'Académie des sciences 1917; 165: 373-375.
12. Summers WC. Bacteriophage therapy. Annu Rev Microbiol 2001; 55: 437-451.
13. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1: 66-85.
14. Chanishvili N. Phage therapy-history from Twort and d'Herelle through soviet experience to current approaches. Adv Virus Res 2012; 83: 3-40.
15. Maura D, Debarbieux L. Bacteriophages as twenty-first century antibacterial tools for food and medicine. Appl Microbiol Biotechnol 2011; 90: 851-859.
16. Thiel K. Old dogma, new tricks-21st century phage therapy. Nat Biotechnol 2004; 22: 31-36.
17. Alemayehu D, Casey PG, McAuliffe O et al. Bacteriophages phimr299-2 and phinh-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012; 3: e00029-12.
18. Debarbieux L, Leduc D, Maura D et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010; 201: 1096-1104.
19. Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 2013; 57: 5961-5968.
20. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention. PLoS One 2011; 6: e16963.
21. Lu JJ, Perng CL, Lee SY, Wan CC. Use of pcr with universal primers and restriction endonuclease digestions for detection and identification of common bacterial pathogens in cerebrospinal fluid. J Clin Microbiol 2000; 38: 2076-2080.
22. Mowat E, Paterson S, Fothergill JL et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am J Respir Crit Care Med 2011; 183: 1674-1679.
23. Workentine ML, Sibley CD, Glezerson B et al. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE 2013; 8: e60225.
24. Hoyland-Kroghsbo NM, Maerkedahl RB, Svenningsen SL. A quorum-sensing-induced bacteriophage defense mechanism. MBio 2013; 4: e00362-00312.
25. Debarbieux L. Bacterial sensing of bacteriophages in communities: The search for the rosetta stone. Curr Opin Microbiol 2014; 20C: 125-130.
26. Pirnay JP, De Vos D, Verbeken G et al. The phage therapy paradigm: Pret-a-porter or sur-mesure? Pharm Res 2011; 28: 934-937.
27. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol 2013; 8: 769-783.